Pfizer and BIND Therapeutics Sign Nanotech Drug Deal

April 3, 2013 | BIND Therapeutics (recently rechristened from BIND Biosciences) has signed a $160 million per drug collaboration with Pfizer to develop targeted medicines with nanotechnology. BIND is developing an experimental group of targeted, programmable medicines called Accurins to treat cancer, heart disease, and inflammatory disorders. Boston Globe